公开(公告)号：EP1221444B1

公开(公告)日：2005-08-31

申请号：EP00940909.5

申请日：2000-06-30

申请人： Eisai Co., Ltd.

发明人： ASANO, Osamu ,  HARADA, Hitoshi ,  YOSHIKAWA, Seiji ,  WATANABE, Nobuhisa ,  INOUE, Takashi ,  HORIZOE, Tatsuo ,  YASUDA, Nobuyuki ,  OHASHI, Kaya ,  MINAMI, Hiroe ,  NAGAOKA, Junsaku ,  MURAKAMI, Manabu ,  KOBAYASHI, Seiichi ,  TANAKA, Isao ,  KAWATA, Tsutomu ,  SHIMOMURA, Naoyuki ,  AKAMATSU, Hiroshi ,  OZEKI, Naoki ,  SHIMIZU, Toshikazu ,  HAYASHI, Kenji ,  HAGA, Toyokazu ,  NEGI, Shigeto ,  NAITO, Toshihiko

IPC分类号： C07D473/34 ,  C07D473/18 ,  C07D471/08 ,  C07D473/40 ,  C07D239/48 ,  C07D213/73 ,  C07D213/75 ,  C07D235/18 ,  C07D471/04 ,  C07D487/04 ,  C07D401/12

CPC分类号： C07D471/04 ,  C07D473/00 ,  C07D473/34 ,  C07D473/40

公开(公告)号：EP1221444A1

公开(公告)日：2002-07-10

申请号：EP00940909.5

申请日：2000-06-30

申请人： Eisai Co., Ltd.

发明人： ASANO, Osamu ,  HARADA, Hitoshi ,  YOSHIKAWA, Seiji ,  WATANABE, Nobuhisa ,  INOUE, Takashi ,  HORIZOE, Tatsuo ,  YASUDA, Nobuyuki ,  OHASHI, Kaya ,  MINAMI, Hiroe ,  NAGAOKA, Junsaku ,  MURAKAMI, Manabu ,  KOBAYASHI, Seiichi ,  TANAKA, Isao ,  KAWATA, Tsutomu ,  SHIMOMURA, Naoyuki ,  AKAMATSU, Hiroshi ,  OZEKI, Naoki ,  SHIMIZU, Toshikazu ,  HAYASHI, Kenji ,  HAGA, Toyokazu ,  NEGI, Shigeto ,  NAITO, Toshihiko

IPC分类号： C07D473/34 ,  C07D473/18 ,  C07D471/08 ,  C07D473/40 ,  C07D239/48 ,  C07D213/73 ,  C07D213/75 ,  C07D235/18 ,  C07D471/04 ,  C07D487/04 ,  A61K31/437 ,  A61K31/52 ,  A61K31/522 ,  A61P3/10 ,  A61P43/00

CPC分类号： C07D471/04 ,  C07D473/00 ,  C07D473/34 ,  C07D473/40

摘要： The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action.
That is, it provides a novel condensed imidazole compound which has an adenosine A2 receptor antagonist action, is effective for preventing or treating diabetes mellitus and diabetic complications, and is represented by the formula (I):
(wherein R 1 represents e.g. an amino group which may be substituted with an alkyl group; R 2 represents e.g. hydrogen atom, an alkyl group, a cycloalkyl group or an alkyl group, alkenyl group or alkynyl group which may be substituted with hydrox etc.; R 3 represents e.g. an optionally substituted alkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, pyridinone group, pyrimidinone group or piperadinone group; Ar represents e.g. an optionally substituted aryl or heteroaryl group; and Q and W are the same as or different from each other and each represents N or CH), a pharmacologically acceptable salt or hydrates thereof.